Physician profile
Bridget Cornell
NPI 1528413523
$2,982.16
in general payments reported to CMS, 2019-2025
34 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $770 · 2022: $579 · 2023: $453 · 2024: $905 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,633.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $316.72 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $311.37 | 2021-2025 | Airsupra |
| Amgen INC. | $302.37 | 2021-2025 | Evenity, Prolia |
| Pfizer INC. | $217.77 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $201.15 | 2021-2025 | Invega Sustenna, Spravato |
| Acadia Pharmaceuticals INC | $151.20 | 2022 | |
| Lilly USA, LLC | $144.55 | 2021-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $135.63 | 2021-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $128.46 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.49 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.90 | 2021-2024 | Xifaxan |
| Esperion Therapeutics, INC. | $80.80 | 2021-2023 | Nexletol |
| Ucb, INC. | $75.86 | 2024 | Bimzelx |
| Incyte Corporation | $70.00 | 2024 | Opzelura |
| Janssen Biotech, INC. | $69.24 | 2024 | Tremfya |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $67.16 | 2022-2023 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $55.31 | 2023-2024 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $49.84 | 2021-2023 | Proquad, M-M-R II, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $45.04 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $36.04 | 2024-2025 | |
| Organon LLC | $33.60 | 2023-2024 | |
| Astellas Pharma US INC | $33.05 | 2024 | Veozah |
| Ultragenyx Pharmaceutical INC. | $32.92 | 2022 | |
| Lundbeck LLC | $32.24 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.40 | 2021 | |
| Novartis Pharmaceuticals Corporation | $31.28 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.98 | 2023 | Gvoke Hypopen |
| Sun Pharmaceutical Industries INC. | $19.42 | 2024 | |
| Philips North America LLC | $18.13 | 2023 | |
| Dexcom, INC. | $15.25 | 2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $14.85 | 2023 | Shingrix, Arexvy |
| Exact Sciences Corporation | $14.47 | 2025 | The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $13.80 | 2024 | Korlym |
| Mylan Specialty L.P. | $12.87 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Cornell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.